Windtree announces issuance of patent in Japan for oncology pipeline

Windtree Therapeutics (WINT) announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers.” The patent number is 7603605 and expires in 2040. “Issuance of the new patent for our oncology preclinical aPKCi inhibitor pipeline is an important part of our development strategy,” said Jed Latkin, CEO of Windtree Therapeutics. “We will continue with our intellectual property work to expand our patent portfolio in key markets throughout the world.”